Followers | 196 |
Posts | 24856 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Thursday, September 08, 2022 3:05:18 PM
I think the reason for the partial halt is answered in the lack of a substantial number of placebo arm patients, not in treatment patients. If the placebo arm is no longer happening, then subjecting patients to a delay in treatment is unnecessarily damaging to them. If one is going to move to an ECA, it would be unethical. And given what they knew at that point and the advice they were likely being given from regulators about what was coming, these reforms take many years, I think they knew that continuing was the best route, and that taking in more placebo arm patients was basically no longer feasible and they would get the number of patients in their treatment arm that much faster when everyone already enrolled became a treatment arm patient. There is also the very strong likelihood that the regulator and DSMB agreed on the adjustment without unblinding them in any way, as the Federal Court judge indicated and the interim analysis indicated was the case. So the adjustment to ECA was basically necessary with each regulator, the regulators fully in the know. The adjustment to OS seems to have been a likely necessary and obvious change for much longer than they likely wanted to discuss because the changes would allow critics to make all sorts of unlikely claims, as the court case and Washington Post article discuss.
So they remained silent and followed the previous path until the regulators, lastly the FDA, made a change in rules for ECA and until they had accrued enough time for all patients enrolled to change to OS from PFS, meaning even the last patients enrolled, you want a good amount of time to pass to ensure you have accumulated the time reasonable to calculate OS for all patients. I think the regulator was well aware of what was going on and was basically leading them by the nose though of course the approach of the regulator in the public course of regulation is that they provide no advice and are not responsible. But the reality is likely much closer to the reality much of the time with any regulator, in the US, you consult regularly, and get a lot of direction from that regulator, through informal consultation that is entirely deniable because the consultations are entirely informal and not part of the main process that everyone knows about. It comes with informal calls, lawyers to regulator, question and answers about pending reforms and how best to proceed.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM